Table 1 List of modelling scenarios and key assumptions

From: Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era

Scenario

Result type

Assumptions

Mobility

Waning

Booster uptake

Seasonality

Vaccine policy

Basecase*

-

6-month

Central

Actual

20%

5+ 80% uptake

No return

Behaviour

No change

Central

Actual

20%

5+ 80% uptake

6-month return*

6-month

Central

Actual

20%

5+ 80% uptake

3-month return

3-month

Central

Actual

20%

5+ 80% uptake

3-week return

3-week

Central

Actual

20%

5+ 80% uptake

No boosters

Boosters eligibility/ uptake (relative to second dose levels)

6-month

Central

None

20%

5+ 80% uptake

50+ boosters

6-month

Central

95% in 50+ only

20%

5+ 80% uptake

Actual boosters*

6-month

Central

Age-specific measured uptake as of 14th April 2022. Individuals aged 50 and above have at least 86.1% and at most 96.7% uptake. Individuals aged 15-49 have at least 40% and at most 80.9% uptake, relative to second dose levels of uptake.

20%

5+ 80% uptake

High uptake

6-month

Central

90% in <50 s; 98% in 50+

20%

5+ 80% uptake

Central waning*

Waning

6-month

Central

Actual

20%

5+ 80% uptake

High waning

6-month

High

Actual

20%

5+ 80% uptake

Very high waning

6-month

Very high

Actual

20%

5+ 80% uptake

10%

Seasonality

6-month

Central

Actual

10%

5+ 80% uptake

20%*

6-month

Central

Actual

20%

5+ 80% uptake

30%

6-month

Central

Actual

30%

5+ 80% uptake

40%

6-month

Central

Actual

40%

5+ 80% uptake

5+, 80%*

Vaccine uptake for children

6-month

Central

Actual

20%

5+ 80% uptake

5+, 50%

6-month

Central

Actual

20%

5+ 50% uptake

  1. Scenarios marked with an asterisk (*) are equivalent. Mobility scenarios are shown in Fig. 3. Assumptions for waning scenarios are given in Table S4. Assumptions for vaccine effectiveness against different SARS-CoV-2 variants are given in Table S2. Assumptions for cross-protection against different SARS-CoV-2 variants given prior infection are given in Table S3.
  2. The detailed age-specific probability of receiving a booster vaccine for this scenario is listed in Table S5B in the Supplementary Information.